Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Nele von Horsten (née Handwerker) and Nele Handwerker. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nele von Horsten (née Handwerker) and Nele Handwerker or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

#129: Hope for Myelin Repair: How Stem Cells Could Change the Future of Progressive MS with Dr. Luca Peruzzotti Jametti

39:13
 
Share
 

Manage episode 504164506 series 3562061
Content provided by Nele von Horsten (née Handwerker) and Nele Handwerker. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nele von Horsten (née Handwerker) and Nele Handwerker or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Neural stem cells may calm brain inflammation and enable myelin repair in progressive MS. Safety looks promising; phase-2 planning is underway.

You can read the interview extract on my blog: https://ms-perspektive.com/129-luca-peruzzotti-jametti

Progressive MS needs therapies that work inside the brain. In this episode, Dr. Luca Peruzzotti Jametti explains why remyelination is so hard in humans, how neural stem cells (NSCs) can calm chronic inflammation through paracrine signals, and when true myelin repair may be feasible. We discuss Phase-1 safety data, the road to Phase-2, who might benefit first (likely progressive MS), and how metabolic approaches to mitochondria/bioenergetics could stack with cell therapies. Dr. Jametti also shares a realistic timeline (5–10 years for larger trials) and a hopeful outlook on disability reversal within 10–15 years. Resources and lab/social links below.

We cover:

  • Relapses vs. PIRA and microglia

  • Why human remyelination often stalls

  • NSCs: paracrine effects vs. cell replacement

  • Safety and delivery routes (intraventricular/intrathecal)

  • Who/when to treat; aHSCT sequencing

  • Mitochondrial metabolism strategies and the bigger pipeline

How and where can interested people follow your research activities?

Follow the team via the Progressive MS (Cambridge) Facebook page, BlueSky, and Cambridge lab pages. You can also follow our work through the Progressive MS Alliance and the RESTORE consortium.

Dr. Luca Peruzzotti Jametti on PubMed

References & Related Episodes/Topics ---

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.

  continue reading

123 episodes

Artwork
iconShare
 
Manage episode 504164506 series 3562061
Content provided by Nele von Horsten (née Handwerker) and Nele Handwerker. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nele von Horsten (née Handwerker) and Nele Handwerker or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Neural stem cells may calm brain inflammation and enable myelin repair in progressive MS. Safety looks promising; phase-2 planning is underway.

You can read the interview extract on my blog: https://ms-perspektive.com/129-luca-peruzzotti-jametti

Progressive MS needs therapies that work inside the brain. In this episode, Dr. Luca Peruzzotti Jametti explains why remyelination is so hard in humans, how neural stem cells (NSCs) can calm chronic inflammation through paracrine signals, and when true myelin repair may be feasible. We discuss Phase-1 safety data, the road to Phase-2, who might benefit first (likely progressive MS), and how metabolic approaches to mitochondria/bioenergetics could stack with cell therapies. Dr. Jametti also shares a realistic timeline (5–10 years for larger trials) and a hopeful outlook on disability reversal within 10–15 years. Resources and lab/social links below.

We cover:

  • Relapses vs. PIRA and microglia

  • Why human remyelination often stalls

  • NSCs: paracrine effects vs. cell replacement

  • Safety and delivery routes (intraventricular/intrathecal)

  • Who/when to treat; aHSCT sequencing

  • Mitochondrial metabolism strategies and the bigger pipeline

How and where can interested people follow your research activities?

Follow the team via the Progressive MS (Cambridge) Facebook page, BlueSky, and Cambridge lab pages. You can also follow our work through the Progressive MS Alliance and the RESTORE consortium.

Dr. Luca Peruzzotti Jametti on PubMed

References & Related Episodes/Topics ---

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.

  continue reading

123 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play